Biosimilar MW032 Vs Denosumab for Solid Tumor–Related Bone Metastases

1. The change of uNTx/uCr (a marker of bone resorption) was within the equivalence margin in the MW032 group and in the denosumab group across the 53 weeks of follow-up. 2. Treatment-related adverse events grade 3 or worse occurred at similar rates across both groups (53.8% in the MW032 group and 57.6% in the denosumab […]

The post Biosimilar MW032 Vs Denosumab for Solid Tumor–Related Bone Metastases first appeared on 2 Minute Medicine.